RE:AZ's PARP + PD-1 CPI hits PFS surrogate endpoint in Phase 3 May 31, 2023 - Astrazeneca's I/O combination study’s primary outcome was progression-free survival (PFS). Compared with standard-of-care chemotherapy, both maintenance arms treated with Imfinzi showed statistically significant and clinically meaningful improvements in PFS. Clinical benefit was greater among patients given Imfinzi and Lynparza.
“These exciting data demonstrate durvalumab immunotherapy can significantly delay disease progression for patients with endometrial cancer and the addition of the PARP inhibitor olaparib can improve the benefit further,”
[ Similar results have been observed with ONCY's Bracelet-1 Phase 2 breast cancer study whereby both pelareorep as a single agent AND pelareorep in combination with the immune checkpoint inhibitor Bravencio demonstrated signifiacant improvements in the measured surrogate endpoints (PFS) at 6 months in comparison with the standard-of-care chemotherapy (paclitaxel). The Bracelet study's PFS continues to mature. ]
https://www.biospace.com/article/astrazeneca-touts-positive-phase-iii-endometrial-cancer-data-for-imfinzi-lynparza/
https://www.clinicaltrialsarena.com/news/oncolytics-biotech-pelareorep/